TL;DR
- A Close-Out Letter is a separate FDA document confirming a firm has corrected the violations cited in an earlier Warning Letter — it does not retract the Warning Letter itself (FDA, About Warning and Close-Out Letters)
- FDA issues one only after it verifies correction, usually at the firm's next inspection, not on request and not on a fixed timeline
- Most Warning Letters never get a public Close-Out Letter at all — correction gets confirmed informally at a later inspection instead of through this specific document
- A Close-Out Letter is a narrower instrument than a consent decree: it closes one letter's citations, not a court-supervised remediation program
- Treating "no close-out letter yet" as a compliance failure is a category error — the letter is a courtesy confirmation, not a required exit ramp
What is an FDA Warning Letter Close-Out Letter?
A Close-Out Letter is FDA's written confirmation that a firm has corrected the specific violations named in one of its Warning Letters. Short document. Narrow scope. It says the citations are resolved — nothing more, and nothing about the firm's compliance status going forward (FDA, About Warning and Close-Out Letters).
It is not automatic. A firm does not earn one by mailing FDA a good written response, even a thorough one. FDA typically wants to see the correction verified in person, which in practice means waiting for the next routine inspection or a targeted follow-up. That's the part compliance teams underestimate: the clock on a Close-Out Letter runs on FDA's inspection schedule, not on how fast the firm fixes the line.
How does a Warning Letter actually get closed out?
The sequence is consistent across therapeutic areas and facility types:
- FDA issues the Warning Letter, and the firm typically has around 15 working days to respond in writing (Argus HQ: how long does a company have to respond to an FDA Warning Letter).
- The firm implements corrective action — new procedures, retraining, equipment changes, whatever the citations demanded.
- FDA evaluates whether that response is adequate on paper. A written response can be found inadequate even when the underlying fix is real, if it doesn't document root cause and a verification plan (Argus HQ: what actually makes a Warning Letter response adequate).
- At a later inspection — sometimes the next scheduled surveillance visit, sometimes a for-cause follow-up — an investigator checks whether the correction actually holds up on the floor, not just on paper.
- If it does, FDA issues the Close-Out Letter and posts it publicly.
Step four is the bottleneck. There's no statutory or regulatory deadline requiring FDA to reinspect a cited firm within any particular window. A firm that fixed its CGMP gaps in month three can still be waiting for its Close-Out Letter in month eighteen, purely because that's when the next inspection landed on the calendar.
Why doesn't every corrected Warning Letter get one?
Because the Close-Out Letter isn't the only way FDA closes a matter internally. A firm can correct its violations, get reinspected, and receive a clean classification — No Action Indicated on the new inspection — without FDA ever issuing a standalone Close-Out Letter tied back to the original Warning Letter. The correction gets absorbed into the new inspection record instead of generating a separate public document.
That gap between "corrected" and "publicly closed out" is exactly why treating the absence of a Close-Out Letter as an open compliance flag is a mistake. A missing Close-Out Letter tells you FDA hasn't published a specific confirmation. It does not tell you the firm is still non-compliant, still under active scrutiny, or heading toward escalation. Those are three different facts, and only a current inspection record — not a search for a missing letter — can tell you which one applies.
| Warning Letter | Close-Out Letter | Consent Decree | |
|---|---|---|---|
| What it confirms | A violation exists and enforcement may follow | The cited violation was corrected | Court-ordered, supervised remediation |
| Who issues it | FDA field office / Center | FDA, after verification | Federal court, at DOJ's request |
| Trigger | Inspection finding meets significance threshold | Verified correction, usually via reinspection | Warning Letter violations recur or go unresolved |
| Guaranteed to happen if corrected | N/A | No — many corrections never get one | N/A |
| Public posting | FDA's searchable Warning Letter database | Separate close-out listing on FDA's site | Federal court docket + DOJ press release |
Sources: FDA, About Warning and Close-Out Letters; Argus HQ: what is an FDA consent decree, and how does a Warning Letter lead to one
What this means for a compliance risk register
- Don't log "no Close-Out Letter" as an open citation. Check the firm's most recent inspection classification instead. That's the current signal; the Close-Out Letter is a lagging one.
- Don't promise a Close-Out Letter timeline to leadership. There isn't one to promise. Point to the next scheduled inspection window instead, since that's the actual trigger event.
- Don't confuse a Close-Out Letter with a clean bill of health. It closes one Warning Letter's citations. It says nothing about citations from a different inspection, a different product line, or a different facility under the same corporate parent.
- Track the underlying correction, not the paperwork. A firm that has genuinely fixed the cited problem is de-risked the moment the fix is verified internally — the public Close-Out Letter, when it eventually arrives, is confirmation for outsiders, not the event that matters for internal risk tracking.
FAQ
Does FDA ever refuse to issue a Close-Out Letter even after correction is verified?
FDA can decline to issue one if the firm's next inspection surfaces new or recurring violations, even unrelated ones, since a Close-Out Letter only covers the original citations and FDA generally won't issue a standalone confirmation on a facility with an open, current problem.
Can a firm request a Close-Out Letter?
A firm can request review of its corrective actions, but FDA controls both the verification method and the timing. There's no petition process that compels FDA to issue the letter on a firm's schedule.
Is a Close-Out Letter the same as passing a follow-up inspection?
Related but not identical. A clean follow-up inspection (No Action Indicated) can happen without FDA ever generating a separate Close-Out Letter tied to the earlier Warning Letter — the correction gets folded into the new inspection record instead.
Do Untitled Letters get Close-Out Letters too?
No. FDA's Close-Out Letter program applies to Warning Letters specifically. Untitled Letters — the lower-severity advisory action — don't carry the enforcement-threat language a Warning Letter does, and they sit outside this close-out process entirely (Argus HQ: what's the difference between an FDA Untitled Letter and a Warning Letter).
Sources: FDA, About Warning and Close-Out Letters. Byline: The Argus Regulatory Analysis Team. Published 2026-07-12.